Latest & greatest articles for Renin Angiotensin System

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Renin Angiotensin System or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Renin Angiotensin System and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Renin Angiotensin System

1. Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: A systematic review and meta-analysis Full Text available with Trip Pro

Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: A systematic review and meta-analysis Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: A systematic review and meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 (...) . Online ahead of print. Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: A systematic review and meta-analysis , Affiliations Expand Affiliation 1 Hypertension Section, Internal Medicine Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. PMID: 32767823 PMCID: DOI: Free PMC article Item in Clipboard Review Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: A systematic review and meta

2020 EvidenceUpdates

2. The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis Full Text available with Trip Pro

The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Diabetes Metab Syndr Actions . 2020 Jun 27;14(5):983-990. doi: 10.1016/j.dsx.2020.06.047. Online ahead of print. The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis , , , , , , , , , Affiliations Expand Affiliations 1 Faculty of Medicine

2020 EvidenceUpdates

3. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. Full Text available with Trip Pro

Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. A potential association between the use of angiotensin-receptor blockers (ARBs) and angiotensin-converting-enzyme (ACE) inhibitors and the risk of coronavirus disease 2019 (Covid-19) has not been well studied.We carried out a population-based case-control study in the Lombardy region of Italy. A total of 6272 case patients in whom infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was confirmed

2020 NEJM

4. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. Full Text available with Trip Pro

Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. There is concern about the potential of an increased risk related to medications that act on the renin-angiotensin-aldosterone system in patients exposed to coronavirus disease 2019 (Covid-19), because the viral receptor is angiotensin-converting enzyme 2 (ACE2).We assessed the relation between previous treatment with ACE inhibitors, angiotensin-receptor blockers, beta-blockers, calcium-channel blockers, or thiazide diuretics

2020 NEJM

5. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Full Text available with Trip Pro

Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Concerns have been raised about the possibility that inhibitors of the renin-angiotensin-aldosterone system (RAAS) could predispose individuals to severe COVID-19; however, epidemiological evidence is lacking. We report the results of a case-population study done in Madrid, Spain, since the outbreak of COVID-19.In this case-population study, we consecutively (...) of cases had pre-existing cardiovascular disease (OR 1·98, 95% CI 1·62-2·41) and risk factors (1·46, 1·23-1·73) than did controls. Compared with users of other antihypertensive drugs, users of RAAS inhibitors had an adjusted OR for COVID-19 requiring admission to hospital of 0·94 (95% CI 0·77-1·15). No increased risk was observed with either angiotensin-converting enzyme inhibitors (adjusted OR 0·80, 0·64-1·00) or angiotensin-receptor blockers (1·10, 0·88-1·37). Sex, age, and background cardiovascular

2020 Lancet

6. The Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A Randomized, Controlled Trial Full Text available with Trip Pro

The Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A Randomized, Controlled Trial The comparative effectiveness of treatment with angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or their combination in people with albuminuria and cardiovascular risk factors is unclear.In a multicenter, randomized, open label, blinded end point trial, we evaluated the effectiveness on cardiovascular events of ACE or ARB

2018 EvidenceUpdates

7. Effect of Losartan on Right Ventricular Dysfunction: Results From the Double-Blind, Randomized REDEFINE Trial (Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-Angiotensin-Aldosterone System) in Adults With Repaired Tetralogy Full Text available with Trip Pro

Effect of Losartan on Right Ventricular Dysfunction: Results From the Double-Blind, Randomized REDEFINE Trial (Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-Angiotensin-Aldosterone System) in Adults With Repaired Tetralogy The effect of angiotensin II receptor blockers on right ventricular (RV) function is still unknown. Angiotensin II receptor blockers are beneficial in patients with acquired left ventricular dysfunction, and recent findings have suggested (...) a favorable effect in symptomatic patients with systemic RV dysfunction. The current study aimed to determine the effect of losartan, an angiotensin II receptor blocker, on subpulmonary RV dysfunction in adults after repaired tetralogy of Fallot.The REDEFINE trial (Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-Angiotensin-Aldosterone System) is an investigator-initiated, multicenter, prospective, 1:1 randomized, double-blind, placebo-controlled study. Adults with repaired

2018 EvidenceUpdates

8. Anti-Inflammatory and Antitumor Effects of Hydroxytyrosol but Not Oleuropein on Experimental Glioma In Vivo. A Putative Role for the Renin-Angiotensin System Full Text available with Trip Pro

Anti-Inflammatory and Antitumor Effects of Hydroxytyrosol but Not Oleuropein on Experimental Glioma In Vivo. A Putative Role for the Renin-Angiotensin System Functional roles of the angiotensin peptides of the renin-angiotensin system (RAS) cascade can be analyzed through their corresponding proteolytic regulatory enzymes aspartyl aminopeptidase (ASAP), aminopeptidase A (APA), aminopeptidase B (APB), aminopeptidase N (APN) and insulin-regulated aminopeptidase (IRAP). These enzyme activities (...) generate active or inactive angiotensin peptides that alter the ratios between their bioactive forms, regulating several important processes such as the regulation of cardiovascular functions, body water regulation, normal memory consolidation and retrieval, but also cell growth, differentiation and apoptosis or the inflammatory response. We have previously described that the treatment with hydroxytyrosol but not with oleuropein or with the mixture of both compounds led to the significant inhibition

2018 Biomedicines

9. How is the Brain Renin-Angiotensin System Regulated? Full Text available with Trip Pro

How is the Brain Renin-Angiotensin System Regulated? 28559391 2018 01 29 2018 11 13 1524-4563 70 1 2017 07 Hypertension (Dallas, Tex. : 1979) Hypertension How Is the Brain Renin-Angiotensin System Regulated? 10-18 10.1161/HYPERTENSIONAHA.117.08550 Nakagawa Pablo P From the Department of Pharmacology, UIHC Center for Hypertension Research, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City. Sigmund Curt D CD From the Department of Pharmacology, UIHC Center (...) Angiotensin II EC 3.4.15.1 Peptidyl-Dipeptidase A EC 3.4.23.15 Renin EC 3.6.1.- Vacuolar Proton-Translocating ATPases IM Angiotensin II metabolism Angiotensinogen metabolism Animals Blood Pressure physiology Brain metabolism Humans Peptidyl-Dipeptidase A metabolism Receptors, Cell Surface metabolism Renin metabolism Renin-Angiotensin System physiology Vacuolar Proton-Translocating ATPases metabolism 2017 6 1 6 0 2018 1 30 6 0 2017 6 1 6 0 ppublish 28559391 HYPERTENSIONAHA.117.08550 10.1161/HYPERTENSIONAHA

2017 Hypertension (Dallas, Tex. : 1979)

10. Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study. Full Text available with Trip Pro

Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study. Objective To examine long term cardiorenal outcomes associated with increased concentrations of creatinine after the start of angiotensin converting enzyme inhibitor/angiotensin receptor blocker treatment.Design Population based cohort study using electronic health records from the Clinical Practice Research Datalink and Hospital Episode Statistics.Setting UK primary care, 1997-2014 (...) .Participants Patients starting treatment with angiotensin converting enzyme inhibitors or angiotensin receptor blockers (n=122 363).Main outcome measures Poisson regression was used to compare rates of end stage renal disease, myocardial infarction, heart failure, and death among patients with creatinine increases of 30% or more after starting treatment against those without such increases, and for each 10% increase in creatinine. Analyses were adjusted for age, sex, calendar period, socioeconomic status

2017 BMJ

11. The Combination of Beta Blockers and Renin-Angiotensin System Blockers Improves Survival in Incident Hemodialysis Patients: A Propensity-Matched Study Full Text available with Trip Pro

The Combination of Beta Blockers and Renin-Angiotensin System Blockers Improves Survival in Incident Hemodialysis Patients: A Propensity-Matched Study Although several studies suggest that the prognosis of hypertensive dialysis patients can be improved by using antihypertensive drug therapy, it is unknown whether the prescription of a particular class or combination of antihypertensive drugs is beneficial during hemodialysis.We performed a propensity score matching study to compare (...) the effectiveness of various classes of antihypertensive drugs on cardiovascular (CV) mortality in 2518 incident hemodialysis patients in Spain. The patients had initially received antihypertensive therapy with a renin-angiotensin system (RAS) blocker (728 patients), a ß-blocker (679 patients), antihypertensive drugs other than a RAS blocker or a ß-blocker (787 patients), or the combination of a ß-blocker and a RAS inhibitor (324 patients). These patients were followed for a maximum of 5 years (median: 2.21 yr

2017 Kidney international reports

12. Early renin?angiotensin system inhibition induced renal deterioration may be a predictor for long-term cardiorenal outcomes

Early renin?angiotensin system inhibition induced renal deterioration may be a predictor for long-term cardiorenal outcomes Early reninangiotensin system inhibition induced renal deterioration may be a predictor for long-term cardiorenal outcomes | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Early reninangiotensin system inhibition induced renal deterioration may be a predictor for long-term cardiorenal outcomes Article Text

2017 Evidence-Based Medicine

13. Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease

Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease Indranil Dasgupta DM FRCP , Debasish Banerjee MD FRCP , Tahseen A Chowdhury MD FRCP , Parijat De MD FRCP , Mona Wahba MA FRCP , Stephen Bain MD FRCP , Andrew Frankel MD FRCP , Damian Fogarty MD FRCP , Ana Pokrajac (...) MD FRCP and Peter Winocour MD FRCP July 2017 Contents Introduction 3 Evidence grades for the recommendations 3 Search strategy 3 1 Hypertension management and renin-angiotensin-aldosterone system blockade in patients with type 1 diabetes 5 Recommendations 6 Audit standards 6 Areas that require further research 7 Introduction 7 Hypertension in patients with type 1 diabetes 8 Modulation of the RAAS in patients with type 1 diabetes 9 2 Hypertension management and renin-angiotensin-aldosterone system

2017 Association of British Clinical Diabetologists

14. Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia?clarification

Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia?clarification Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—clarification, December 2016 - GOV.UK GOV.UK uses cookies to make the site simpler. Search Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—clarification, December 2016 In light of feedback, we have clarified (...) our article on concomitant use of these medicines in heart failure. Published 13 December 2016 From: Therapeutic area: , In February 2016, we published an article about the use of spironolactone and renin-angiotensin system drugs in patients with heart failure. Following publication, we received feedback from a small number of readers and a professional organisation that the article was inconsistent with clinical guidelines. We sought advice from the , who considered that the advice outlined

2017 MHRA Drug Safety Update

15. Importance of endogenous compensatory vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure. (Abstract)

Importance of endogenous compensatory vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure. The magnitude of the clinical benefits produced by inhibitors of the renin-angiotensin system in heart failure has been modest, possibly because of the ability of renin-angiotensin activity to escape from suppression during long-term treatment. Efforts to intensify pharmacological blockade by use of dual inhibitors that interfere (...) with the renin-angiotensin system at multiple sites have not yielded consistent incremental clinical benefits, but have been associated with serious adverse reactions. By contrast, potentiation of endogenous compensatory vasoactive peptides can act to enhance the survival effects of inhibitors of the renin-angiotensin system, as evidenced by trials that have compared angiotensin-converting enzyme inhibitors with drugs that inhibit both the renin-angiotensin system and neprilysin. Several endogenous

2016 Lancet

16. Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia

Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—February 2016 article - GOV.UK GOV.UK uses cookies to make the site simpler. Search Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—February 2016 article Monitoring of blood electrolytes is essential in patients (...) that increases sodium excretion while reducing potassium loss at the distal renal tubule. This mechanism of action means that hyperkalaemia can occur, particularly in patients with impaired renal function. Spironolactone should not be used in patients with severe renal impairment or pre-existing hyperkalaemia. Risk of hyperkalaemia with renin-angiotensin system drugs ACEi are mainly indicated in patients with hypertension or heart failure. ARBs are also indicated in hypertension and some are also indicated

2016 MHRA Drug Safety Update

17. Renin-angiotensin system drugs

Renin-angiotensin system drugs Renin-angiotensin system drugs: dual ther Renin-angiotensin system drugs: dual therap apy y Key therapeutic topic Published: 15 January 2015 nice.org.uk/guidance/ktt2 pathways Options for local implementation Options for local implementation Dual therapy with an angiotensin-converting enzyme (ACE) inhibitor plus an angiotensin receptor blocker (ARB) has only a limited place in treatment, specifically in a small minority of people with heart failure. Review (...) heart failure and there was an increased risk of hyperkalaemia, hypotension, and impaired renal function. See the NICE medicines evidence commentary Efficacy and safety of dual blockade of the renin-angiotensin system for more information. UK Medicines Information (UKMi) has also published a medicines question and answers resource on the rationale and evidence for combining ACE inhibitors with ARBs for treating hypertension and for preventing vascular events. Dual therapy has only a limited place

2015 National Institute for Health and Clinical Excellence - Advice

18. Efficacy and safety of supramaximal titrated inhibition of renin-angiotensin-aldosterone system in idiopathic dilated cardiomyopathy. Full Text available with Trip Pro

Efficacy and safety of supramaximal titrated inhibition of renin-angiotensin-aldosterone system in idiopathic dilated cardiomyopathy. The optimal dosing strategies for blocking the renin-angiotensin-aldosterone system in idiopathic dilated cardiomyopathy (IDCM) are poorly known. We sought to determine the long-term efficacy and safety of supramaximal titration of benazepril and valsartan in patients with IDCM.480 patients with IDCM in New York Heart Association functional class II-IV

2015 ESC heart failure Controlled trial quality: uncertain

19. Case?control: Cotrimoxazole is associated with sudden death in older patients receiving inhibitors of renin?angiotensin system

Case?control: Cotrimoxazole is associated with sudden death in older patients receiving inhibitors of renin?angiotensin system Cotrimoxazole is associated with sudden death in older patients receiving inhibitors of reninangiotensin system | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Cotrimoxazole is associated with sudden death in older patients receiving inhibitors of reninangiotensin system Article Text Aetiology/Harm Case–control

2015 Evidence-Based Medicine

20. Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. Full Text available with Trip Pro

Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. To determine whether the prescription of co-trimoxazole with an angiotensin converting enzyme inhibitor or angiotensin receptor blocker is associated with sudden death.Population based nested case-control study.Ontario, Canada, from 1 April 1994 to 1 January 2012.Ontario residents aged 66 years or older treated with an angiotensin converting enzyme inhibitor or angiotensin (...) prolongation) was also associated with an increased risk of sudden death (adjusted odds ratio 1.29, 1.03 to 1.62), but no such risk was observed with nitrofurantoin or norfloxacin.In older patients receiving angiotensin converting enzyme inhibitors or angiotensin receptor blockers, co-trimoxazole is associated with an increased risk of sudden death. Unrecognized severe hyperkalemia may underlie this finding. When appropriate, alternative antibiotics should be considered in such patients.© Fralick et al

2014 BMJ